MICHAEL ITTMANN to Disease Models, Animal
This is a "connection" page, showing publications MICHAEL ITTMANN has written about Disease Models, Animal.
Connection Strength
0.534
-
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013 May 01; 73(9):2718-36.
Score: 0.188
-
Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res. 2013 Apr 15; 73(8):2551-62.
Score: 0.046
-
Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer. J Urol. 2007 Oct; 178(4 Pt 1):1521-7.
Score: 0.032
-
Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 2004 Mar 15; 64(6):2270-305.
Score: 0.025
-
Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res. 2003 Sep 15; 63(18):5754-60.
Score: 0.024
-
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate. 2003 May 15; 55(3):219-37.
Score: 0.024
-
Systemic Ablation of Camkk2 Impairs Metastatic Colonization and Improves Insulin Sensitivity in TRAMP Mice: Evidence for Cancer Cell-Extrinsic CAMKK2 Functions in Prostate Cancer. Cells. 2022 06 10; 11(12).
Score: 0.022
-
Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer. Cancer Discov. 2020 09; 10(9):1374-1387.
Score: 0.019
-
Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat Metab. 2019 01; 1(1):70-85.
Score: 0.017
-
Influence of the neural microenvironment on prostate cancer. Prostate. 2018 Feb; 78(2):128-139.
Score: 0.016
-
Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. J Clin Invest. 2016 07 01; 126(7):2626-41.
Score: 0.015
-
Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. Clin Cancer Res. 2016 08 01; 22(15):3937-49.
Score: 0.014
-
Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene. 2016 11 17; 35(46):5963-5976.
Score: 0.014
-
Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression. Horm Cancer. 2015 Jun; 6(2-3):67-86.
Score: 0.013
-
Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A. 2014 Feb 04; 111(5):E592-600.
Score: 0.012
-
FGFR1-WNT-TGF-? signaling in prostate cancer mouse models recapitulates human reactive stroma. Cancer Res. 2014 Jan 15; 74(2):609-20.
Score: 0.012
-
ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity. Mol Cancer Res. 2013 Jul; 11(7):736-47.
Score: 0.012
-
COUP-TFII inhibits TGF-?-induced growth barrier to promote prostate tumorigenesis. Nature. 2013 Jan 10; 493(7431):236-40.
Score: 0.011
-
Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Int J Cancer. 2008 Aug 01; 123(3):543-51.
Score: 0.008
-
Hypoxic adipocytes pattern early heterotopic bone formation. Am J Pathol. 2007 Feb; 170(2):620-32.
Score: 0.008